peanut307 said...
...It's interesting to me in that within the Chaartered, Stampede and other studies none of them did a control arm with chemo only. All were either chemo+ADT or ADT alone.
The trial design was done that way for both trials to compare the standard of care to a new dosing or regimen. At the time of the CHAARTED trial started the standard of care for these men was an LHRH agonist with an AR drug. At that time the AR drug of choice was Casodex. It was never just docetaxel as that was always considered an after everything else failed treatment (TAX327 Trial led to the release of docetaxel and was not compared without the disease already being resistant to HT).
Midway through the CHAARTED trial, around 2010, new drugs started to hit the market that were in fact competing for this trial patient.